| Literature DB >> 26023350 |
Molouk Jaafarpour1, Masoud Hatefi2, Fatemeh Najafi3, Javaher Khajavikhan4, Ali Khani3.
Abstract
BACKGROUND: Primary dysmenorrhea with interferes in daily activities can have adverse effects on quality of life of women.Entities:
Keywords: Complementary Therapies; Herbal Medicine; Nausea; Pain; Vomiting
Year: 2015 PMID: 26023350 PMCID: PMC4443385 DOI: 10.5812/ircmj.17(4)2015.27032
Source DB: PubMed Journal: Iran Red Crescent Med J ISSN: 2074-1804 Impact factor: 0.611
Figure 1.Flow Chart
Baseline Characteristics of the Participants [a]
| Characteristic | Placebo (n = 38) | Cinnamon (n = 38) | P Value[ |
|---|---|---|---|
|
| 1.5 ± 21.3 | 1.1 ± 20.7 | 0.135 |
|
| 0.8 ± 13.4 | 0.8 ± 13.3 | 0.116 |
|
| 1.5 ± 27.8 | 1.5 ± 27.4 | 0.487 |
|
| 0.9 ± 14.6 | 0.5 ± 14.3 | 0.476 |
|
| 6.1 ± 1.1 | 1.3 ± 6.3 | 0.090 |
a Values are presented as mean ± SD.
b P > 0.05.
Kolmogorov–Smirnov Test [a]
| Parameters | K-S | P Value | Parameters | K-S | P Value | Parameters | K-S | P Value |
|---|---|---|---|---|---|---|---|---|
|
| 0.796 | 0.555 | Pain 8 | 0.813 | 0.638 | Bleeding 24 | 0.629 | 0.429 |
|
| 0.913 | 0.386 | Pain 16 | 0.504 | 0.368 | Bleeding 48 | 0.819 | 0.338 |
|
| 0.657 | 0.486 | Pain 24 | 0.681 | 0.593 | Bleeding 72 | 0.749 | 0.628 |
|
| 0.589 | 0.674 | Pain 48 | 0.938 | 0.654 | Nausea | 0.563 | 0.364 |
|
| 0.847 | 0.538 | Pain72 | 0.727 | 0.433 | Nausea 24 | 0.486 | 0.377 |
|
| 0.719 | 0.439 | Pain duration | 0.438 | 0.322 | Nausea 48 | 0.538 | 0.467 |
|
| 0.691 | 0.518 | Duration 24 | 0.549 | 0.738 | Nausea 72 | 0.613 | 0.489 |
|
| 0.739 | 0.345 | Duration 48 | 0.582 | 0.623 | Vomiting 24 | 0.764 | 0.513 |
|
| 0.489 | 0.636 | Duration 72 | 0.648 | 0.389 | Vomiting 48 | 0.839 | 0.360 |
|
| 0.949 | 0.421 | Bleeding | 0.864 | 0.512 | Vomiting 72 | 0.693 | 0.459 |
aAbbreviation: K-S, Kolmogorov–Smirnov.
Outcome of Severity of Pain Between Groups[a]
| Pain Score by vas at Various Intervals, h | Placebo (n = 38) | Cinnamon (n = 38) | P Value |
|---|---|---|---|
|
| 1 ± 7.5 | 1 ± 7.4 | 0.569 [ |
|
| 7.3 ± 0.6 | 7.1 ± 0.7 | 0.00 [ |
|
| 7.1 ± 0.9 | 6.8 ± 0.7 | 0.00 [ |
|
| 6.8 ± 0.7 | 6.6 ± 0.4 | 0.00 [ |
|
| 6.7 ± 0.7 | 6.4 ± 0.6 | 0.00 [ |
|
| 6.5 ± 0.7 | 5.9 ± 0.9 | 0.00 [ |
|
| 6.3 ± 0.4 | 4.3 ± 0.7 | 0.00 [ |
|
| 6.1 ± 0.4 | 4.1 ± 0.5 | 0.00 [ |
|
| 5.3 ± 0.6 | 3.2 ± 0.6 | 0.00 [ |
|
| 4.0 ± 0.3 | 1.8 ± 0.4 | 0.00 [ |
a Values are presented as mean ± SD.
b P > 0.05.
c P < 0.001.
Outcome of Duration of Pain Between Groups[a]
| Duration of Pain, hour | Placebo (n = 38) | Cinnamon (n = 38) | P Value |
|---|---|---|---|
|
| 2.3 ± 26.5 | 2.3 ± 27.2 | 0.359 [ |
|
| 25.2 ± 1.9 | 16.5 ± 1.6 | 0.00 [ |
|
| 21.2 ± 1.5 | 8.0 ± 0.9 | 0.00 [ |
|
| 18.7 ± 1.3 | 3.2 ± 0.4 | 0.00 [ |
a Values are presented as mean ± SD.
b P > 0.05.
c P < 0.001.
Outcome of the Amount of Menstrual Bleeding Between Groups [a]
| Amount of Menstrual Bleeding (Number of Used Pad) | Placebo (n = 38) | Cinnamon (n = 38) | P Value |
|---|---|---|---|
| Scanty (1 pad) | 3 (7.8) | 4 (10.5) | 0.251 [ |
| Average (2-3 pads) | 23 (60.5) | 22 (57.8) | 0.181 [ |
| Excessive (≥ 4 pads) | 12 (31.5) | 12 (31.5) | 0.274 [ |
|
| |||
| Scanty (1 pad) | 4 (10.5) | 7 (18.4) | 0.032 [ |
| Average (2-3 pads) | 23 (60.5) | 25 (65.7) | 0.061 [ |
| Excessive (≥ 4 pads) | 11 (28.9) | 6 (15.7) | 0.037 [ |
|
| |||
| Scanty (1 pad) | 6 (15.7) | 17 (44.7) | 0.012 [ |
| Average (2-3 pads) | 23 (60.5) | 20 (52.6) | 0.031 [ |
| Excessive (≥ 4 pads) | 9 (23.6) | 1 (2.6) | 0.00 [ |
|
| |||
| Scanty (1 pad) | 11 (18.4) | 27 (71.05) | 0.00 d |
| Average (2-3 pads) | 23 (60.5) | 11 (28.9) | 0.00 [ |
| Excessive (≥ 4 pads) | 3 (7.8) | 0 (0.00) | 0.00 [ |
a Values are presented as No. (%).
b P > 0.05.
c P < 0.05.
d P < 0.001.
Outcome of Severity of Nausea and Vomiting Between Groups [a, b]
| Nausea Score by VAS at Various Intervals, h | Placebo (n = 38) | Cinnamon (n = 38) | P Value |
|---|---|---|---|
|
| 5.8 ± 2.1 | 5.6 ± 1.8 | 0.09 |
|
| 5.5 ± 1.9 | 4.1 ± 1.6 | 0.01 [ |
|
| 4.7 ± 2.2 | 2.6 ± 1.4 | 0.00 [ |
|
| 3.3 ± 1.6 | 0.5 ± 1.1 | 0.00 [ |
|
| |||
|
| |||
| non | 25 (65.7) | 26 (68.4) | 0.06[ |
| 1-2 | 11 (28.9) | 10 (26.3) | 0.18[ |
| ≥ 3 | 2 (5.2) | 2 (5.2) | 0.08[ |
|
| |||
| non | 26 (68.4) | 32 84.2) | 0.01 [ |
| 1-2 | 10 (26.3%) | 5 (13.1) | 0.00 [ |
| ≥ 3 | 2 (5.2%) | 1 (2.6) | 0.04 [ |
|
| |||
| non | 29 (76.3) | 36 (94.7) | 0.00 [ |
| 1-2 | 7 (18.4) | 2 (5.2) | 0.00 [ |
| ≥ 3 | 2 (5.2) | 0 (0.00) | 0.00 [ |
|
| |||
| non | 31 (81.5) | 38 (100) | 0.00 [ |
| 1-2 | 7 (18.4) | 0 (0.00) | 0.00 [ |
| ≥ 3 | 0 (0.00) | 0 (0.00) | 0.00 |
aAbbreviation: VAS, Visual analogue scale.
bValues are presented as mean ± SD or No. (%).
c P < 0.05.
d P < 0.001.
eP > 0.05.